NO20052842L - Antilymfom malrettede midler med effektor og affinitetsfunksjoner linket av en trifunksjonell reagent - Google Patents
Antilymfom malrettede midler med effektor og affinitetsfunksjoner linket av en trifunksjonell reagentInfo
- Publication number
- NO20052842L NO20052842L NO20052842A NO20052842A NO20052842L NO 20052842 L NO20052842 L NO 20052842L NO 20052842 A NO20052842 A NO 20052842A NO 20052842 A NO20052842 A NO 20052842A NO 20052842 L NO20052842 L NO 20052842L
- Authority
- NO
- Norway
- Prior art keywords
- effector
- lymphoma
- targeted agents
- functions linked
- trifunctional reagent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Sammendrag Det beskrives et medisinsk middel omfattende et reagens konjugert til et anti-lymfom-antistoff, og likeledes et kitt inneholdende nevnte medisinske middel, og anvendelse av nevne medisinske middel, samt en fremgangemåte for å behandle lymfom. Midlet kan omfatte en effektor, for eksempel et antitumormiddel eller en diagnostisk markør, og en affinitetsligand som muliggjør ekstrakorporeal klaring av midlet. De tre komponentene er bundet av en trifunksjonell linker.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43301202P | 2002-12-13 | 2002-12-13 | |
SE0203731A SE0203731D0 (sv) | 2002-12-13 | 2002-12-13 | Reagent |
PCT/SE2003/001949 WO2004054615A1 (en) | 2002-12-13 | 2003-12-12 | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052842D0 NO20052842D0 (no) | 2005-06-13 |
NO20052842L true NO20052842L (no) | 2005-09-12 |
Family
ID=32599441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052842A NO20052842L (no) | 2002-12-13 | 2005-06-13 | Antilymfom malrettede midler med effektor og affinitetsfunksjoner linket av en trifunksjonell reagent |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1569690B1 (no) |
JP (1) | JP2006511532A (no) |
KR (1) | KR20050086907A (no) |
AU (1) | AU2003287131B2 (no) |
BR (1) | BR0316599A (no) |
CA (1) | CA2509103A1 (no) |
MX (1) | MXPA05006306A (no) |
NO (1) | NO20052842L (no) |
PL (1) | PL377213A1 (no) |
RU (1) | RU2005122033A (no) |
WO (1) | WO2004054615A1 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
AU2004291141B2 (en) * | 2003-11-17 | 2009-06-11 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
FR2875410B1 (fr) | 2004-09-23 | 2012-11-16 | Guerbet Sa | Composes de diagnostique pour le ciblage de recpteur a chimiokines |
KR100699278B1 (ko) * | 2005-05-12 | 2007-03-23 | 학교법인 포항공과대학교 | 수화젤레이터로 유용한 바이오틴-아미노산 결합체 및이로부터 제조된 수화젤 |
BRPI0817182A2 (pt) | 2007-10-30 | 2015-03-17 | Genentech Inc | Método para purificar um anticorpo e composições |
SI3320912T1 (sl) | 2008-04-17 | 2021-08-31 | Io Biotech Aps | Imunoterapija na osnovi indolamin 2, 3-dioksigenaze |
NZ590358A (en) | 2008-07-23 | 2012-04-27 | Hanmi Holdings Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
US20210231652A1 (en) * | 2018-05-31 | 2021-07-29 | George Mason Research Foundation, Inc. | Organometallic labels for the detection of biomolecules, methods of synthesis and processes for conjugating an organometallic labels to a biomolecule |
JPWO2022224980A1 (no) | 2021-04-20 | 2022-10-27 | ||
KR20230119859A (ko) * | 2022-02-08 | 2023-08-16 | 연세대학교 산학협력단 | 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010023288A1 (en) * | 1999-07-07 | 2001-09-20 | Wilbur D. Scott | Trifunctional reagent for conjugation to a biomolecule |
WO2000002050A1 (en) * | 1998-07-07 | 2000-01-13 | Department Of Radiation Oncology, University Of Washington | Trifunctional reagent for conjugation to a biomolecule |
NZ573838A (en) * | 1998-08-11 | 2011-01-28 | Biogen Idec Inc | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
US20020009444A1 (en) * | 2000-04-25 | 2002-01-24 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
-
2003
- 2003-12-12 MX MXPA05006306A patent/MXPA05006306A/es unknown
- 2003-12-12 RU RU2005122033/15A patent/RU2005122033A/ru not_active Application Discontinuation
- 2003-12-12 JP JP2004560221A patent/JP2006511532A/ja active Pending
- 2003-12-12 KR KR1020057010811A patent/KR20050086907A/ko not_active Application Discontinuation
- 2003-12-12 EP EP03781200A patent/EP1569690B1/en not_active Expired - Lifetime
- 2003-12-12 CA CA002509103A patent/CA2509103A1/en not_active Abandoned
- 2003-12-12 PL PL377213A patent/PL377213A1/pl not_active IP Right Cessation
- 2003-12-12 AU AU2003287131A patent/AU2003287131B2/en not_active Ceased
- 2003-12-12 BR BR0316599-0A patent/BR0316599A/pt not_active IP Right Cessation
- 2003-12-12 WO PCT/SE2003/001949 patent/WO2004054615A1/en active Application Filing
-
2005
- 2005-06-13 NO NO20052842A patent/NO20052842L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2003287131B2 (en) | 2008-07-24 |
WO2004054615A1 (en) | 2004-07-01 |
JP2006511532A (ja) | 2006-04-06 |
BR0316599A (pt) | 2005-10-04 |
EP1569690A1 (en) | 2005-09-07 |
PL377213A1 (pl) | 2006-01-23 |
NO20052842D0 (no) | 2005-06-13 |
AU2003287131A1 (en) | 2004-07-09 |
EP1569690B1 (en) | 2011-07-27 |
CA2509103A1 (en) | 2004-07-01 |
KR20050086907A (ko) | 2005-08-30 |
MXPA05006306A (es) | 2005-09-21 |
RU2005122033A (ru) | 2006-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052842L (no) | Antilymfom malrettede midler med effektor og affinitetsfunksjoner linket av en trifunksjonell reagent | |
DE69728585D1 (de) | Mittel gegen Juckreiz | |
UA95438C2 (ru) | Биспецифические антитела, которые замещают функциональные белки | |
PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
WO2007006041A8 (en) | Imaging and therapeutic method using monocytes | |
TR200103756T2 (tr) | Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi. | |
TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
BR0309254A (pt) | Uso de um anticorpo anti-ctla-4 | |
CY1113190T1 (el) | Μεθοδος αγωγης της αιμολυτικης νοσου | |
WO2004018000A3 (en) | Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents | |
WO2006015079A3 (en) | Erm family binding agents and their use in diagnosis and treatment of proliferative conditions | |
BRPI0511187A (pt) | método para tratar cáncer em um indivìduo | |
CY1109817T1 (el) | Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου | |
DE60140069D1 (de) | Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür | |
GB9806762D0 (en) | Treatment and diagnosis of staphylococcal infections | |
WO2006078853A3 (en) | Thioredoxin interacting protein (txnip) as regulator of vascular function | |
NO20032244D0 (no) | Brönnbehandlingsprosess | |
WO2004029214A8 (en) | Lfa-1 alpha subunit antibodies and methods of use | |
SE0203731D0 (sv) | Reagent | |
WO2001085980A3 (en) | Enzymatic assays for screening anti-cancer agents | |
WO2004047757A3 (en) | Diagnosing and treating hematopoietic cancers | |
EP1629009B8 (en) | Compositions comprising large and small binding fragments of antibodies against the same toxin | |
ATE401895T1 (de) | Antipruritisches mittel | |
BR0212446A (pt) | Uso de 4-piridilmetilftalazinas para tratamento de câncer | |
WO2002056755A3 (en) | Method for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |